Lorie Ellis

1.6k total citations
82 papers, 1.3k citations indexed

About

Lorie Ellis is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Lorie Ellis has authored 82 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 15 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Immunology. Recurrent topics in Lorie Ellis's work include Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Biosimilars and Bioanalytical Methods (11 papers). Lorie Ellis is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Biosimilars and Bioanalytical Methods (11 papers). Lorie Ellis collaborates with scholars based in United States, Canada and Belgium. Lorie Ellis's co-authors include Mary Frances Picciano, Patrick Lefèbvre, Karin Yurko‐Mauro, Kim N. Green, Hilda Martínez‐Coria, Margit Hamosh, Frank M. LaFerla, Dominic Pilon, Andrea M. Mastro and Theresa R. Henderson and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and Blood.

In The Last Decade

Lorie Ellis

72 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lorie Ellis United States 20 342 324 210 174 155 82 1.3k
Otávio Rizzi Coelho Brazil 23 155 0.5× 148 0.5× 171 0.8× 225 1.3× 174 1.1× 76 1.8k
Konrad Szymañski Poland 18 102 0.3× 444 1.4× 81 0.4× 95 0.5× 41 0.3× 44 1.3k
Gabriela Torres-Mejı́a Mexico 25 138 0.4× 211 0.7× 157 0.7× 54 0.3× 91 0.6× 82 1.7k
Jane J. Kim United States 19 90 0.3× 128 0.4× 412 2.0× 216 1.2× 49 0.3× 31 1.8k
Pedro Valdivielso Spain 25 86 0.3× 98 0.3× 324 1.5× 114 0.7× 50 0.3× 143 2.0k
Věra Adámková Czechia 23 107 0.3× 58 0.2× 215 1.0× 91 0.5× 69 0.4× 125 2.0k
Hakan Kültürsay Türkiye 22 92 0.3× 133 0.4× 178 0.8× 303 1.7× 49 0.3× 86 1.6k
Leon Bernal‐Mizrachi United States 16 167 0.5× 114 0.4× 143 0.7× 270 1.6× 20 0.1× 46 1.7k
Adi Mehta Canada 18 48 0.1× 343 1.1× 120 0.6× 67 0.4× 43 0.3× 37 1.7k
Ann M. Dnistrian United States 24 164 0.5× 410 1.3× 97 0.5× 122 0.7× 220 1.4× 44 1.9k

Countries citing papers authored by Lorie Ellis

Since Specialization
Citations

This map shows the geographic impact of Lorie Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorie Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorie Ellis more than expected).

Fields of papers citing papers by Lorie Ellis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorie Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorie Ellis. The network helps show where Lorie Ellis may publish in the future.

Co-authorship network of co-authors of Lorie Ellis

This figure shows the co-authorship network connecting the top 25 collaborators of Lorie Ellis. A scholar is included among the top collaborators of Lorie Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorie Ellis. Lorie Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lowentritt, Benjamin, et al.. (2025). Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer. Advances in Therapy. 42(7). 3437–3454.
3.
4.
Gaylis, Franklin, Bruno Émond, Ameur M. Manceur, et al.. (2024). Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer. Journal of health economics and outcomes research. 109–117. 3 indexed citations
5.
Lowentritt, Benjamin, Dominic Pilon, Erik Muser, et al.. (2024). Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).. Journal of Clinical Oncology. 42(4_suppl). 51–51. 1 indexed citations
6.
7.
Lowentritt, Benjamin, Gordon Brown, Dominic Pilon, et al.. (2022). Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer. Urology. 166. 182–188. 4 indexed citations
8.
Cohen, Stanley, Joel M. Kremer, Kimberly J. Dandreo, et al.. (2019). Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clinical Rheumatology. 38(9). 2501–2508. 1 indexed citations
9.
Tkacz, Joseph, et al.. (2019). Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis. Clinical Therapeutics. 41(6). 1080–1089.e5. 8 indexed citations
10.
Pilon, Dominic, et al.. (2016). Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. Journal of Managed Care & Specialty Pharmacy. 23(2). 225–235. 13 indexed citations
11.
Kozma, Chris M, et al.. (2015). Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders. Journal of Medical Economics. 18(8). 646–653. 2 indexed citations
12.
13.
Ellis, Lorie, S. Bolge, & Patricia Rice. (2014). Golimumab Utilization Patterns And Refill Adherence In Patients With Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis. Value in Health. 17(3). A49–A50. 3 indexed citations
14.
Lafeuille, Marie‐Hélène, et al.. (2013). Observed Abiraterone Acetate Utilization By Prostate Cancer (Pc) Patients In A Large Administrative Claims Database In The United States. Value in Health. 16(3). A144–A144. 1 indexed citations
15.
16.
Green, Kim N., et al.. (2007). Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels. Journal of Neuroscience. 27(16). 4385–4395. 262 indexed citations
17.
Hamosh, Margit, et al.. (1997). Digestive Enzymes in Human Milk: Stability at Suboptimal Storage Temperatures. Journal of Pediatric Gastroenterology and Nutrition. 24(1). 38–43. 27 indexed citations
18.
Ellis, Lorie, Andrea M. Mastro, & Mary Frances Picciano. (1997). Do Milk-Borne Cytokines and Hormones Influence Neonatal Immune Cell Function?. Journal of Nutrition. 127(5). 985S–988S. 59 indexed citations
19.
Ellis, Lorie, Andrea M. Mastro, & Mary Frances Picciano. (1996). Milk-borne prolactin and neonatal development. Journal of Mammary Gland Biology and Neoplasia. 1(3). 259–269. 27 indexed citations
20.
Pereira, Gilberto R., Stephen Baumgart, Michael J. Bennett, et al.. (1994). Use of high-fat formula for premature infants with bronchopulmonary dysplasia: Metabolic, pulmonary, and nutritional studies. The Journal of Pediatrics. 124(4). 605–611. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Otávio Rizzi Coelho Breakdown of academic impact, for papers by Konrad Szymañski Breakdown of academic impact, for papers by Gabriela Torres-Mejı́a Breakdown of academic impact, for papers by Jane J. Kim Breakdown of academic impact, for papers by Pedro Valdivielso Breakdown of academic impact, for papers by Věra Adámková Breakdown of academic impact, for papers by Hakan Kültürsay Breakdown of academic impact, for papers by Leon Bernal‐Mizrachi Breakdown of academic impact, for papers by Adi Mehta Breakdown of academic impact, for papers by Ann M. Dnistrian
Rankless by CCL
2026